In recent years, there has been a significant
increase in breast cancer diagnoses worldwide. Breast tumor is a multifaceted illness
that need a multidisciplinary come up to treatment. ENHERTU is a medication
used in the treatment of breast cancer, specifically in patients with
HER2-positive metastatic breast cancer who have received at least two prior
anti-HER2 regimens. In this article, we will explore ENHERTU, its mechanism of
action, dosage, side effects, and clinical trials.
ENHERTU: Mechanism of Action
ENHERTU is an antibody-drug conjugate that targets
HER2-positive breast cancer cells. It is composed of an anti-HER2 monoclonal
antibody, a cleavable tetrapeptide-based linker, and a potent topoisomerase I
inhibitor. Upon binding to HER2-positive cells, ENHERTU is internalized, and
the topoisomerase I inhibitor is released, leading to cell death.
Dosage and Administration
ENHERTU is available as a lyophilized powder for
reconstitution and intravenous infusion. The recommended dosage is 5.4 mg/kg of
body weight every three weeks, with a maximum dose of 500 mg. The infusion
should be administered over 30 to 90 minutes.
Side Effects
Like all medications, ENHERTU can cause side
effects. The most common side effects include nausea, vomiting, fatigue,
decreased appetite, hair loss, and diarrhea. ENHERTU can also cause serious
side effects, such as interstitial lung disease, embryo-fetal toxicity, and
infusion-related reactions.
Clinical Trials
The efficacy and safety of ENHERTU have been
evaluated in several clinical trials. The DESTINY-Breast01 trial was a
randomized, open-label, phase 3 study that compared ENHERTU with standard
treatment in patients with HER2-positive metastatic breast cancer who had
received at least two prior anti-HER2 regimens. The trial showed that ENHERTU
significantly improved progression-free survival and overall survival compared
to standard treatment.
Conclusion
ENHERTU is an important medication in the treatment
of HER2-positive metastatic breast cancer. Its mechanism of action, dosage,
side effects, and clinical trials have been thoroughly evaluated, making it a
viable treatment option for patients. As with all medications, it is important
to consult with a healthcare professional before starting treatment with
ENHERTU.
0 Comments